Middle East & Africa Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)
The influenza vaccines market in Middle East & Africa is expected to grow from US$ 374.35 million in 2022 to US$ 533.85 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
Strong Pipeline Candidates for Influenza Vaccines
Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats.
Market Overview
The Middle East & Africa Influenza Vaccines Market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. In 2021, South Africa was the largest market for Influenza Market in the region. The market for Influenza Market in the Middle East & Africa is anticipated to grow at a CAGR of 6.1% during the forecast period The influenza vaccines market is expected to grow due to the huge population base, increasing cases of influenza, and growing research studies across the region. Moreover, growing healthcare facilities help propel the market growth. Saudi Arabia is one of the important countries in the Middle Eastern region that has significant scope for the influenza vaccines market. The healthcare system in the country is developing at a rapid pace as well as increasing number of international companies are developing medical and research teams in the country. A sharp increase in the state health budget is also expected to drive the growth of the influenza vaccines market in the country.
Saudi Arabia is among the fastest growing regions in the Middle East & Africa whose growth is driven by a huge population base with chronic diseases. According to the latest WHO data published in 2020 Influenza and Pneumonia Deaths in Saudi Arabia reached 6,132 or 4.58% of total deaths. The age-adjusted Death Rate is 30.87 per 100,000 of population ranks Saudi Arabia 82 in the world. In 2009, in response to the pandemic Influenza A(H1N1)pdm09, the public health department at the Ministry of Health in Saudi Arabia established its first case-based Influenza surveillance system. In Saudi Arabia, rising healthcare spending and well-established hospital and tertiary care centers fuel the growth of the market. The government has increased healthcare and social affairs expenditure by 48% to US$ 42.64 billion (SR160bn) for the development of new healthcare centers, hospitals, and primary care centers. Thus, such initiatives by the government, and penetration of international market players are expected to drive the growth of influenza vaccines market in Saudi Arabia.
Middle East & Africa Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Middle East & Africa Influenza Vaccines Market Segmentation
The Middle East & Africa Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.
Based on vaccine type, the Middle East & Africa influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.
Based on virus type, the Middle East & Africa influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.
Based on technology, the Middle East & Africa influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.
Based on route of administration, the Middle East & Africa influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.
Based on country, the market is segmented into the UAE, Saudi Arabia, South Africa, and the rest of Middle East & Africa. Saudi Arabia dominated the market share in 2022.
AstraZeneca; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Middle East & Africa.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Influenza Vaccines Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook